By admin 
The highly anticipated results from the Phase 3 HORIZON trial, presented at the American Heart Association’s (AHA) Scientific Sessions in Chicago and published in the New England Journal of Medicine, have sent shockwaves through the cardiology community. For years, Lipoprotein(a), or Lp(a), has been identified as a significant, genetically determined risk factor for cardiovascular disease that remains largely untouched by standard-of-care treatments like statins. The pharmaceutical industry has been in a high-stakes race to develop a targeted therapy that could finally address this "hidden" driver of heart disease. However, the failure of Novartis’s pelacarsen to meet its primary endpoint—despite successfully and dramatically lowering Lp(a) levels—has raised fundamental questions about the biology of the lipid and the future of the therapeutic field.
Lipoprotein(a) is a complex particle consisting of a low-density lipoprotein (LDL)-like particle and a specific protein called apolipoprotein(a). Approximately one in five people worldwide carry high levels of Lp(a), a condition determined almost entirely by genetics rather than diet or lifestyle. Because of its structural similarity to plasminogen, Lp(a) is believed to be both pro-atherogenic (promoting the buildup of fatty plaques in the arteries) and pro-thrombotic (increasing the risk of blood clots). For patients who have already suffered a heart attack or stroke, elevated Lp(a) represents a "residual risk" that persists even if their LDL cholesterol is brought down to record lows.
The HORIZON trial was designed to be the definitive proof-of-concept for the "Lp(a) hypothesis"—the idea that lowering this specific particle would translate directly into a reduction in major adverse cardiovascular events (MACE). The study enrolled 8,323 participants with established cardiovascular disease and baseline Lp(a) levels of 70 mg/dL or higher. These patients were randomized to receive either monthly injections of pelacarsen, an antisense oligonucleotide developed in collaboration with Ionis Pharmaceuticals, or a placebo.
Over a median follow-up period of nearly five years, the data confirmed that pelacarsen was exceptionally effective at its biochemical task. The drug reduced Lp(a) levels by an average of 80% or more, maintaining those reductions throughout the duration of the study. However, this physiological success did not translate into clinical benefit. The researchers reported no statistically significant difference between the pelacarsen group and the placebo group in the occurrence of heart attacks, strokes, urgent coronary revascularization, or cardiovascular death. The primary composite endpoint occurred in a similar percentage of patients in both arms, leading to a trial result that many experts described as "sobering" and "perplexing."
The failure of the HORIZON trial has prompted an immediate and deep dive into the underlying data to understand why a drug that did exactly what it was designed to do failed to save lives or prevent disability. Several theories have emerged among the investigators and independent cardiologists attending the AHA sessions. One prominent hypothesis is the "too little, too late" argument. The participants in the HORIZON trial already had advanced, established cardiovascular disease. It is possible that by the time a patient has reached this stage, the inflammatory and structural damage caused by decades of high Lp(a) exposure is no longer reversible simply by lowering the levels of the particle in the bloodstream. In this view, Lp(a)-lowering therapies might need to be administered much earlier in life—perhaps decades before the first heart attack—to show a meaningful clinical benefit.
Another possibility involves the baseline characteristics of the trial participants. In the HORIZON trial, patients were already receiving aggressive background therapy, including high-intensity statins and, in some cases, PCSK9 inhibitors. These treatments are highly effective at lowering overall cardiovascular risk. It is possible that the "floor" of risk had already been reached for these patients, making it statistically difficult for a new drug to show incremental improvement unless the study was much larger or lasted significantly longer. Furthermore, while pelacarsen lowered Lp(a) by 80%, some researchers question whether even that reduction was sufficient. Unlike LDL cholesterol, where a 30 mg/dL drop can lead to a predictable reduction in risk, the "exchange rate" for Lp(a) might be much higher, requiring massive absolute reductions to move the needle on clinical outcomes.
The results also raise a more uncomfortable question: Is Lp(a) a causal driver of disease, or merely a marker of it? While vast Mendelian randomization studies have strongly suggested a causal link between high Lp(a) genes and heart disease, the HORIZON results provide the first major clinical evidence that contradicts the "lower is better" mantra that has dominated lipidology for decades. If Lp(a) is not as direct a cause of arterial plaque as previously thought, the entire pipeline of drugs currently in development could be at risk.
The pharmaceutical landscape for Lp(a) is crowded, with several other major players watching the Novartis data closely. Amgen is currently conducting its own Phase 3 trial, known as OCEAN(a)-Outcomes, for its drug olpasiran. Unlike pelacarsen, which is an antisense oligonucleotide, olpasiran utilizes small interfering RNA (siRNA) technology to silence the gene responsible for Lp(a) production. Eli Lilly is also in the fray with lepodisiran, another siRNA candidate that has shown the ability to reduce Lp(a) by up to 94% in early-stage trials. Silence Therapeutics is developing zerlasiran, which is also in mid-to-late-stage clinical testing.
The failure of pelacarsen does not necessarily mean these other drugs will fail, but it does heighten the stakes. The siRNA drugs generally achieve even deeper and more sustained reductions in Lp(a) than antisense oligonucleotides. If the issue in the HORIZON trial was a matter of "potency"—that 80% reduction wasn’t enough—then the 90%+ reductions seen with siRNA might still prove successful. However, if the issue is the timing of intervention or a fundamental misunderstanding of the particle’s role in late-stage disease, the entire class could face a difficult path toward regulatory approval and clinical adoption.
From a patient perspective, the news is a significant setback. For the millions of people who have been told they have a high genetic risk for heart disease that cannot be treated, pelacarsen was a beacon of hope. Currently, the only FDA-approved treatment for high Lp(a) is lipoprotein apheresis—a process similar to dialysis where the blood is filtered to remove the particles. This process is time-consuming, expensive, and available at only a few specialized centers. The hope was that a simple monthly injection would replace this cumbersome procedure.
Despite the primary endpoint failure, Novartis and the HORIZON investigators are looking for "silver linings" in the secondary data. There were signals in certain subgroups that may suggest some benefit, though these must be interpreted with extreme caution to avoid "p-hacking" or finding patterns in noise. The safety profile of pelacarsen remained favorable, with no major concerns regarding liver toxicity or platelet counts, which had been a concern with earlier generations of antisense drugs. This safety data is crucial, as any future trials in younger, healthier populations would require an impeccable safety record to justify long-term use.
The medical community now looks toward the next two years, when the results from Amgen’s OCEAN(a) trial are expected. That trial may clarify whether the HORIZON results were specific to pelacarsen’s mechanism or a broader indictment of the Lp(a) hypothesis. In the meantime, the takeaway for clinicians is a return to basics. For patients with high Lp(a), the focus remains on "controlling the controllable"—managing blood pressure, treating LDL cholesterol to the lowest possible levels, and ensuring lifestyle factors like smoking and diabetes are strictly managed to offset the unaddressed genetic risk.
The HORIZON trial serves as a potent reminder of the rigors of drug development. In the transition from successful Phase 2 biomarkers to Phase 3 clinical outcomes, many promising therapies fall into the "valley of death." While pelacarsen successfully mastered the biochemistry, it failed to conquer the biology of human disease in this specific context. Whether this is the end of the road for pelacarsen or the beginning of a more nuanced understanding of genetic heart disease remains to be seen. What is certain is that the journey to neutralize Lipoprotein(a) has become significantly more complex, and the cardiology world will be debating these results for years to come.
